Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 12, 3051-3061

Molecular Characterization and Prevalence of Antibiotic Resistance in Helicobacter pylori Isolates in Kuala Lumpur, Malaysia


Molecular Characterization and Prevalence of Antibiotic Resistance in Helicobacter pylori Isolates in Kuala Lumpur, Malaysia

Alfizah Hanafiah et al. Infect Drug Resist.


Aims and objectives: Helicobacter pylori has been classified as high priority pathogen by the WHO in 2017. The emergence of antibiotic-resistant strains is one of the main causes of treatment failure in H. pylori infection. This study determined and characterized primary and secondary resistances in H. pylori in Malaysia.

Materials and methods: Gastric biopsies from antrum (n=288) and corpus (n=283) were obtained from 288 patients who underwent endoscopy at Universiti Kebangsaan Malaysia Medical Center (UKMMC), Kuala Lumpur, Malaysia. Antibiotic susceptibility to six classes of antibiotics was determined by the E-test. Mutations conferring in resistance in functional genes were identified by PCR and sequencing.

Results: Overall resistance rates to metronidazole, clarithromycin and levofloxacin were 59.3% (35/59), 35.6% (21/59) and 25.4% (15/59), respectively. Secondary isolates showed significantly higher resistance rates to clarithromycin compared to the primary isolates. Mixed infection with susceptible and resistant isolates was observed in 16.2% (6/37) of cases, of which 83.3% (n=5) had infection with the same strain. 41% (18/44) of isolates were resistant to more than one class of antibiotics of which 50% (9/18) were multidrug-resistant, two being primary and seven being secondary isolates. Mutations in rdxA, 23S rRNA and gyrA genes were associated with resistance to metronidazole, clarithromycin and levofloxacin, respectively.

Conclusion: The high level of resistance to metronidazole, clarithromycin and levofloxacin seen in H. pylori isolates in our setting warrants the need for continuous surveillance and highlights caution in use of antibiotics generally used as first-line therapy in H. pylori eradication regimen.

Keywords: Helicobacter pylori; antibiotic resistance; clarithromycin; levofloxacin; metronidazole; point mutation.

Conflict of interest statement

HB received a scholarship from the Universiti Kebangsaan Malaysia under the postgraduate “Zamalah” program. The authors declare no other conflicts of interest in this work.

Similar articles

See all similar articles

Cited by 1 PubMed Central articles


    1. Hooi JKY, Lai WY, Ng WK. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 2017;153:420–429. - PubMed
    1. Ozbey G, Demirel U, Aygun C, Ertas HB. Investigation of the association between clinical outcome and the cag pathogenicity-island and other virulence genes of Helicobacter pylori isolates from patients with dyspepsia in Eastern Turkey. Brazilian J Microbiol. 2013;44(4):1267–1274. doi:10.1590/S1517-83822013000400034 - DOI - PMC - PubMed
    1. Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev. 2000;22(2):283–297. doi:10.1093/oxfordjournals.epirev.a018040 - DOI - PubMed
    1. Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents (update 2016). J Pediatr Gastroenterol Nutr. 2017;64(6):991–1003. - PubMed
    1. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection – the Maastricht IV/Florence Consensus Report. Gut. 2012;61(5):646–664. doi:10.1136/gutjnl-2012-302084 - DOI - PubMed

LinkOut - more resources